Biotech Catalysts This Week: 4 Trial Completions and 9 New Financings (Oct 18-25, 2026)
This week brings no FDA decision dates, but four trial primary completions are estimated, including two povorcitinib studies in prurigo nodularis from INCY and a cutaneous lupus erythematosus study of litifilimab from BIIB. Last week saw two FDA approvals, for IRD and IBRX, alongside eight new company-guided timelines and twelve key SEC filings, with no delays or discontinuations recorded.
At a glance: this week no FDA decision dates, 4 Phase 2 or 3 trials reaching primary completion and 9 new financing filings. Last week: 2 FDA decisions, 8 new timelines announced and 12 key SEC filings.
🔄 What Changed Last Week
New timelines announced in press releases:
- TLSA, intranasal foralum: Q1 2027. “Topline data are anticipated to be announced in Q1 2027.” SEC filing
- EPRX, RESOLVE: December 2026. “The interim data from the Phase 2b portion of the RESOLVE trial are expected in December 2026.” SEC filing
- CBIO, CR-001 (SKB118) and sac-TMT: mid-2027. “A Phase 2 trial of CR-001 (SKB118) and sac-TMT in participants with locally advanced or metastatic NSCLC is ongoing with initial data expected in mid-2027;” SEC filing
- ONCY, pelareorep: fourth quarter of 2026. “Oncolytics expects to report final results from Cohort 4 in the fourth quarter of 2026.” SEC filing
- CRVO, nfvPPA: in October 2026. “CervoMed reported initial 12-week biomarker data from its ongoing Phase 2a clinical trial in nfvPPA in October 2026 and expects to present 24-week biomarker data at CTAD in…” SEC filing
- TCRT, VLR199: in 2028. “We believe this transaction and the concurrent private placement provide a strong financial foundation for us to advance an exciting pipeline and offer our stockholders a…” SEC filing
- ZBIO, SunStone: in 4Q 2026. “Phase 2 SunStone trial in Systemic Lupus Erythematosus (SLE) topline results expected in 4Q 2026.” SEC filing
- AQST, Anaphylm: in Q4 2026. “In parallel, we are advancing our commercial preparations so that we are ready for the potential launch of Anaphylm, if approved.” Aquestive continues to advance its ex-U.S.…” SEC filing
FDA decisions:
- IRD Phentolamine Ophthalmic Solution 0.75%: approved (2026-10-17)
- IBRX ANKTIVA: approved (2026-10-14)
Trial status changes on ClinicalTrials.gov:
- IVVD: Phase 3 trial marked completed (2026-10-15). Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadminis Registry
📄 Key SEC Filings Last Week
Filings that can move a stock, each summarized from the filing itself; financing filings are under Dilution Watch below:
- KRYS, 2026-10-15 (clinical trial): Reported early proof-of-concept data for KB113 in three Gorlin syndrome patients: over 80% of assessed basal cell carcinoma lesions regressed (69 of 83), including non-injected lesions. Company is discussing advanced development with the FDA. SEC filing
- EPRX, 2026-10-15 (clinical trial): Reached its 120-patient enrollment target on October 12, 2026 in the placebo-controlled Phase 2b portion of the RESOLVE trial of EP-104GI for eosinophilic esophagitis. Over 3,000 injections given with no treatment-related serious adverse events; interim Phase 2b analysis expected December 2026. SEC filing
- PHAR, 2026-10-14 (clinical trial): Pharming reported positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation, presented at ESID 2026. The filing references a press release for details and figures. SEC filing
- ONCY, 2026-10-14 (clinical trial): Expects a final grant payment from the Pancreatic Cancer Action Network this quarter as GOBLET enrollment winds down. Final Cohort 4 results are expected in Q4 2026 and initial Cohort 5 results in the first half of 2027. SEC filing
- COYA, 2026-10-14 (clinical trial): Coya plans an open-label extension of its ALSTARS Phase 2/3 trial of COYA 302 in ALS, starting November 2026, and has delayed the planned FTD Phase 2 trial start from the second half of 2026 to 2027. Cash runway into the second half of 2027 is unchanged. SEC filing
- ASND, 2026-10-16 (regulatory): CHMP adopted a positive opinion recommending EU marketing authorization for once-weekly TransCon CNP (navepegritide) for achondroplasia in children two years and older with open epiphyses. The final European Commission decision is expected in Q4 2026, with a first EU launch as YUVIWEL in Germany planned for Q1 2027. SEC filing
- LEGN, 2026-10-15 (regulatory): Legend Biotech said the FDA cleared its IND application for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T therapy for relapsed or refractory B-cell malignancies. The company plans a U.S. Phase 1/2 study. SEC filing
- AVXL, 2026-10-15 (regulatory): FDA cleared Anavex’s IND for blarcamesine in Fragile X syndrome, allowing a planned Phase 2a study of about 60 adult males. Blarcamesine has Orphan Drug Designation for this indication, and no FDA-approved treatment exists. SEC filing
- MEDS, 2026-10-16 (deal): DataMeds signed an exclusive US license with REBOOT Health AI for GLP-1 direct-to-consumer use, issuing 666,667 shares plus a $50,000 payment and revenue sharing. Nasdaq flagged stockholders’ equity of $(12,447,801) and the company is converting debt into stock. SEC filing
- SNTI, 2026-10-15 (deal): Shareholders reconvened the 2026 annual meeting and approved the Merger Agreement with ST NewCo Limited, a reverse stock split of 1-for-20 to 1-for-50 at the Board’s discretion, and Nasdaq 5635(d) approval for issuance above 19.99% upon exchange of Midco notes. SEC filing
- OCGN, 2026-10-15 (deal): Ocugen signed an exclusive license with Roots Pharmaceutical for OCU400, its retinitis pigmentosa gene therapy, in the Middle East and North Africa. Ocugen gets up to $4 million in upfront and development payments, up to $255.0 million in sales milestones, and 22% royalties on net sales. SEC filing
- MBIO, 2026-10-15 (listing): Nasdaq granted Mustang Bio an additional 180-day period, until April 12, 2027, to regain compliance with the $1.00 minimum bid price requirement. The company may effect a reverse stock split if necessary. SEC filing
🧪 Phase 2 and 3 Trials Reaching Primary Completion
Estimated primary completion dates from ClinicalTrials.gov: the last patient reaches the main endpoint. Topline results usually follow weeks or months later.
- INCY, 2026-10-19 (Phase 3): A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) Registry
- INCY, 2026-10-19 (Phase 3): A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) Registry
- BIIB, 2026-10-20 (Phase 2/3): A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus Registry
- AZN, 2026-10-23 (Phase 2): This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight Registry
📡 Run-up Radar Highlights
Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):
- ZURA: Phase 2 primary completion in 14 days, score 79/100
- VSTM: Data readout guided for October 2026, window closes in 13 days, score 74/100
- IMUX: Phase 3 primary completion in 14 days, score 72/100
💸 Dilution Watch: New Financing Filings
- MEDS: private placement (8-K, 2026-10-16) EDGAR
- MAZE: private placement (8-K, 2026-10-16) EDGAR
- ALEC: ATM program up to $125M (424B5, 2026-10-16) EDGAR
- ALXO: private placement (8-K, 2026-10-15) EDGAR
- SILO: private placement (8-K, 2026-10-14) EDGAR
- TCRT: private placement (8-K, 2026-10-13) EDGAR
- HLSQ: private placement (8-K, 2026-10-13) EDGAR
- CDT: private placement (8-K, 2026-10-13) EDGAR
- ADCT: private placement (8-K, 2026-10-13) EDGAR
📉 Downside Radar: Trading Far Below a Recent Offering
Of biotech stocks 25% or more below their close on the day of a recent offering, 76% were lower 60 trading days later, median -29% (any biotech on a random day: 53% lower, median -2%). On the radar now:
- DCOY: $1.17, 70% below $3.85, its close on the day of its Sep 23 private placement (new this week)
- MDCX: $3.25, 60% below $8.15, its close on the day of its Sep 11 private placement (new this week)
- LEXX: $2.86, 57% below $6.60, its close on the day of its Sep 9 private placement (new this week)
- BKHA: $6.01, 51% below $12.19, its close on the day of its Sep 24 private placement (new this week)
- GRML: $6.00, 49% below $11.85, its close on the day of its Sep 28 registered direct offering (new this week)
- JUNS: $2.90, 49% below $5.66, its close on the day of its Aug 24 private placement (new this week)
- KZIA: $7.25, 47% below $13.77, its close on the day of its Aug 31 underwritten offering (new this week)
- JAGX: $3.52, 41% below $6.02, its close on the day of its Sep 28 private placement (new this week)
Full Downside Radar and how it was tested →
📈 Last Week’s Biggest Gainers
- ESLA +68.35% (volume 45.9x average)
- MXCT +29.63% (volume 16.2x average)
- INDP +28.96% (volume 1.5x average)
- LQDA +26.59% (volume 7.1x average)
- HUMA +24.12% (volume 3.1x average)
Earlier weekly catalyst recaps →
Track your tickers on the BioRadar dashboard →
This digest is for informational purposes only and is not investment advice. Always do your own research.